NCT02467335View on ClinicalTrials.gov

Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

52

Participants

Timeline

Start Date

January 29, 2015

Primary Completion Date

October 3, 2015

Study Completion Date

October 3, 2015

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG

BMS-663068

BMS-663068

Trial Locations (1)

08690

GSK Investigational Site, Hamilton

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY